LLT-A2

LLT-A2 is a preclinical-stage drug-eluting contact lens being developed by **MediPrint Ophthalmics** for the treatment of **ocular allergy**. The product utilizes the company's proprietary **MediPrint™** 3D printing technology to incorporate an active pharmaceutical ingredient—likely an antihistamine or mast cell stabilizer—directly into a contact lens. This platform is designed to provide sustained, continuous release of medication to the ocular surface, aiming to improve therapeutic outcomes and patient compliance compared to traditional topical eye drops, which are often limited by rapid tear washout and poor adherence.